Bausch Health Companies (NYSE:BHC) Price Target Cut to $9.00 by Analysts at Jefferies Financial Group

Bausch Health Companies (NYSE:BHC) had its target price trimmed by Jefferies Financial Group from $13.00 to $9.00 in a research report report published on Wednesday morning, BayStreet.CA reports. The firm currently has a buy rating on the stock.

Several other brokerages also recently commented on BHC. Scotiabank lowered their price objective on shares of Bausch Health Companies from $10.00 to $8.50 and set a sector perform rating for the company in a research report on Friday, August 2nd. StockNews.com raised Bausch Health Companies from a hold rating to a buy rating in a report on Saturday, July 27th. Raymond James initiated coverage on Bausch Health Companies in a research report on Wednesday, July 10th. They set a market perform rating and a $8.00 price objective for the company. Royal Bank of Canada decreased their target price on Bausch Health Companies from $10.00 to $8.50 and set a sector perform rating on the stock in a research report on Friday, August 2nd. Finally, Truist Financial dropped their target price on shares of Bausch Health Companies from $8.00 to $7.00 and set a hold rating for the company in a report on Thursday, July 25th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of Hold and a consensus target price of $7.33.

Bausch Health Companies Stock Down 1.1 %

BHC stock opened at $5.42 on Wednesday. Bausch Health Companies has a 52 week low of $3.96 and a 52 week high of $11.46. The business has a 50-day simple moving average of $6.58 and a 200 day simple moving average of $7.82. The company has a market cap of $1.96 billion, a PE ratio of -4.37 and a beta of 0.77.

Bausch Health Companies (NYSE:BHC) last released its earnings results on Thursday, August 1st. The company reported $0.98 EPS for the quarter, beating the consensus estimate of $0.89 by $0.09. Bausch Health Companies had a negative net margin of 5.12% and a negative return on equity of 813.85%. The firm had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.33 billion. During the same period last year, the firm earned $0.81 EPS. On average, analysts anticipate that Bausch Health Companies will post 3.58 EPS for the current fiscal year.

Institutional Investors Weigh In On Bausch Health Companies

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. International Assets Investment Management LLC bought a new stake in shares of Bausch Health Companies during the fourth quarter worth about $185,000. Mackenzie Financial Corp grew its holdings in Bausch Health Companies by 26.9% during the 4th quarter. Mackenzie Financial Corp now owns 1,562,694 shares of the company’s stock worth $12,543,000 after acquiring an additional 331,462 shares during the last quarter. Duality Advisers LP increased its position in Bausch Health Companies by 20.4% in the 4th quarter. Duality Advisers LP now owns 88,449 shares of the company’s stock valued at $709,000 after acquiring an additional 15,001 shares during the period. Fountainhead AM LLC raised its stake in shares of Bausch Health Companies by 4.7% during the fourth quarter. Fountainhead AM LLC now owns 359,516 shares of the company’s stock valued at $2,883,000 after acquiring an additional 15,976 shares during the last quarter. Finally, Bfsg LLC acquired a new position in shares of Bausch Health Companies during the fourth quarter worth $63,000. Institutional investors own 78.65% of the company’s stock.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.